Latest Breaking News On - Prnewswire seelos therapeutics inc - Page 1 : comparemela.com

Seelos Therapeutics Announces Pricing of $1 1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of.

United statesNew yorkNewport beachMike moyerAnthony marcianoPrnewswire seelos therapeutics incSeelos therapeutics incRoth capital partnersLifesci advisorsExchange commissionCapital partnersClemente driveSecurities actSeelos therapeuticsAcute suicidal ideationMajor depressive disorder

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAnthony marcianoMike moyerLifesci advisorsSeelos therapeutics incPrnewswire seelos therapeutics incNasdaq capital marketNasdaq capitalSeelos therapeuticsAcute suicidal ideationMajor depressive disorderLooking statementsPrivate securities litigation reform actAnnual reportQuarterly reports

Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAnthony marcianoTim whitakerRaj mehraUs department of defenseCenters for diseasePrnewswire seelos therapeutics incLifesci advisorsAgency for healthcare researchExchange commissionJavelin pharmaceuticals inc hospiraDrug administrationSeelos therapeutics incTherapeutics announces receiptUnited states food

Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote FOR All Proxy Proposals at the Special Meeting to be held on January 10, 2024

NEW YORK, Jan. 2, 2024 /PRNewswire/ Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare.

New yorkUnited statesAnthony marcianoMike moyerPrnewswire seelos therapeutics incSeelos therapeutics incLifesci advisorsInstitutional shareholder servicesMorrow sodaliExchange commissionSpecial meetingSeelos boardProxy statementAcute suicidal ideationMajor depressive disorderPrivate securities litigation reform act

Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote FOR All Proxy Proposals At The Special Meeting To Be Held On January 1

Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote FOR All Proxy Proposals At The Special Meeting To Be Held On January 1
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAnthony marcianoMike moyerLifesci advisorsPrnewswire seelos therapeutics incExchange commissionMorrow sodaliSeelos therapeutics incInstitutional shareholder servicesSpecial meetingSeelos boardProxy statementAcute suicidal ideationMajor depressive disorderPrivate securities litigation reform act